These anti-GARP antibodies, blocking the GARP-TGF-β interaction, could have advantage in cancer by transiently inhibiting the immunosuppressive function of Tregs without physically eliminating them, as this is the case for CTLA-4 antibodies [74,75]. The gene discussed is LRRC32; the disease is cancer.